Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
The MURANO study (NCT02005471) is a Phase III trial looking at rituximab in combination with either bendamustine or venetoclax for the treatment of refractory chronic lymphocytic Leukemia (CLL). A key...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
MURANO update: MRD, biological subsets & amp; safety analysis
MURANO (NCT02005471) is a Phase III randomized trial comparing the efficacy of venetoclax plus rituximab vs. standard chemoimmunotherapy of bendamustine plus rituximab in relapsed/refractory chronic l...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
MURANO update: MRD negativity in CLL
The MURANO trial (NCT02005471) compared the benefit of venetoclax plus rituximab vs. bendamustine plus rituximab in chronic lymphocytic leukemia (CLL), for which further results were presented at the ...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Devise Future Trials That Add Another Agent Potentially Carfilzomib, Venetoclax, & Bendamustine
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, talks about Devising Future Trials That Add Another Agent Potentially Carfilzomib, Venetoclax, & Bendamustine at ASCO 2...
Author: Annual-Meeting
Added: 06/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Bendamustine plus rituximab vs. standard therapy for advanced CLL
Fludarabine, cyclophosphamide and rituximab (FCR) is the standard chemotherapy regimen used to treat chronic lymphocytic leukaemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Ho...
Author: VJHemOnc
Added: 02/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 5, 2018 Category: Cancer & Oncology Source Type: podcasts
Rituximab After Bendamustine - Rituximab Maintenance Improved PFS
John M. Burke, MD from Rocky Mountain Cancer Centers discusses Rituximab after Bendamustine - Rituximab maintenance improved PFS at the 2017 American Society of Hematology.
Author: ASHReport
Added: 01/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 12, 2018 Category: Cancer & Oncology Source Type: podcasts
Atezolizumab + Bendamustine & Obinutuzumab - No major safety signals in follicular lymphoma
John M. Burke, MD from Rocky Mountain Cancer Centers discusses Atezolizumab + Bendamustine & Obinutuzumab and no major safety signals in follicular lymphoma at the 2017 American Society of Hematology.
Author: ASHReport
Added: 01/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Trial results of idelalisib with bendamustine and rituximab in CLL
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the results of a Phase III trial of bendamustine and rituximab plus placebo vs bendamustine and rituximab ...
Author: VJHemOnc
Added: 07/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - July 5, 2016 Category: Cancer & Oncology Source Type: podcasts
Discussion of a Phase III trial evaluating the efficacy and safety of idelalisib
Jacqueline Barrientos, MD from Northwell Health, New York, NY discuss a placebo-controlled study of idelalisib in combination with bendamustine plus rituximab, also known as BR (NCT01569295). The resu...
Author: VJHemOnc
Added: 07/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - July 5, 2016 Category: Cancer & Oncology Source Type: podcasts
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY gives a brief overview of relapsed/refractory chronic lymphocytic leukemia (CLL) and describes the results of a P...
Author: PatientPowerEU
Added: 03/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2016 Category: Cancer & Oncology Source Type: podcasts
Obinutuzumab (GA101) plus bendamustine as front-line therapy in CLL
Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, talks about one of the arms of the Phase IIIb GREEN clinical trial, of obinutuzumab (GA101) plus bendamustine in chron...
Author: VJHemOnc
Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts
Side-effect of idelalisib and its use in chronic lymphocytic leukemia
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY discusses common side-effects observed in the Phase III clinical trial of idelalisib plus bendamustine and rituxi...
Author: VJHemOnc
Added: 02/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 11, 2016 Category: Cancer & Oncology Source Type: podcasts
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a Phase III clinical trial of idelalisib plus bendamustine and rituximab in relapsed/refr...
Author: VJHemOnc
Added: 02/10/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 10, 2016 Category: Cancer & Oncology Source Type: podcasts
ASH Clinical News: Obinutuzumab Extends Remission Time in Rituximab-Refractory iNHL
ASH Clinical News talks to Laurie Sehn, MD, MPH, about the “remarkable” results from the phase III GADOLIN trial – the first randomized trial to investigate obinutuzumab plus bendamustine in patients ...
Author: ash
Added: 12/21/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 21, 2015 Category: Cancer & Oncology Source Type: podcasts
